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This paper introduces HealthAgents, an EC-funded research project to improve the classification of brain tumours through 
multi-agent decision support over a distributed network of local databases or Data Marts. HealthAgents will not only develop 
new pattern recognition methods for a distributed classification and analysis of in vivo MRS and ex vivo/in vitro HRMAS 
and DNA data, but also define a method to assess the quality and usability of a new candidate local database containing a set 
of new cases, based on a compatibility score.  
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1 INTRODUCTION 
Brain tumours remain an important cause of morbidity and mortality in Europe. Diagnosis using 
Magnetic Resonance Imaging (MRI) is non-invasive, but only achieves 60-90% accuracy depending on the 
tumour type and grade. The current gold standard classification of brain tumours by biopsy and 
histopathological analysis involves invasive surgical procedure and incurs a risk.  
 
Nowadays the diagnosis and treatment of brain tumours is typically based on clinical symptoms, 
radiological appearance and often a histopathological diagnosis of a biopsy. However, treatment response of 
histologically or radiologically-similar tumours can vary widely, particularly in children. Magnetic 
Resonance Spectroscopy (MRS) is a non-invasive technique for determining the tissue biochemical 
composition (metabolomic profile) of a tumour. Additionally, the genomic profile, determined using DNA 
microarrays, facilitates the classification of tumour grades and types not trivially distinguished by 
morphologic appearance.  
 
Thus, we propose the definition of a decision support system (DSS) which employs MRS and genomic 
profiles. This DSS will deploy an ad hoc agent-based architecture in order to negotiate a distributed 
diagnostic tool for brain tumours, implement data mining techniques, transfer clinical data and extract 
information. The distributed nature of our approach will help the users to observe local centre policies for 
sharing information whilst allowing them to benefit from the use of distributed data warehouse (d-DWH). 
Moreover, it will permit the design of local classifiers targeting a specific patient population. 
 
We argue that this new information for classifying tumours along with clinical data, should be securely 
and easy accessible in order to improve the diagnosis and prognosis of tumours. All data will be stored 
anonymously, and securely through a network of data marts based on all this information acquired and stored 
at centres throughout Europe. This network will grant bona-fide access to an organisation in return for its 
contribution of clinical data to a d-DWH/Decision Support System (d-DSS). 
 
This rest of this paper is structured as follows. First, we provide some background on the underlying 
technologies for this project: brain tumour detection and agent technology. Then we provide the architectural 
specification. Finally, we conclude with our future work. 
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2.1 Brain Tumour Diagnosis 
Brain tumours remain an important cause of morbidity and mortality and afflict an increasing 
percentage of the aging adult with a crude incidence rate of 8 per 100,000 inhabitants in Europe [2]. In 
children over 1 year of age, brain tumours are the most common solid malignancies that cause disease-
related death.  
Diagnosis using Magnetic Resonance Imaging (MRI) is non-invasive, but only achieves 60-90% 
accuracy depending on the tumour type and grade [10]. The current gold standard classification of a brain 
tumour by histopathological analysis of biopsy is an invasive surgical procedure and incurs a risk of 2.4-
3.5% morbidity and 0.2-0.8% mortality, in addition to healthcare costs and stress to patients. For tumours 
that evolve slowly (e.g. pilocytic astrocytoma in children), repeated biopsies may not be advisable or 
practical. There is a need to improve brain tumour classification, and to provide non-invasive methods for 
brain tumour diagnosis and prognosis, to aid patient management and treatment. Three techniques are 
available to address these needs: 
1. Magnetic Resonance Spectroscopy (MRS) [7] is a non-invasive technique that provides biochemical 
information on tissue in vivo.  
2. HR-MAS [1,13] is applied to biopsies in vitro in order to improve characterisation. Also, DNA 
microarray analysis of biopsies can determine tumour phenotype from gene expression profiles and predict 
better survival than classical histology [16,17].  
3. MRS, coupled with conventional MRI, provides metabolite profiles of a single voxel (SV) of 
tumour tissue [7,19] (see Fig. 1). It also produces a molecular image of particular tumour metabolites in 10 
minutes using multi-voxel (MV) techniques (Fig. 2).  
 
2.2 Agent technology 
Several modern complex distributed systems are composed of customisable building blocks, known as 
agents. Surveys on agent technology enumerate four important characteristics of agent technology [3]. First, 
agents possess an internal knowledge-based state that can be dynamically altered. Second, they have 
dynamic reasoning capabilities that determine their internal behaviour through constraints or goals. Third, 
they sustain a communication status that enables them to interact with agents or human entities. Last, they 
feature a unique identity that provides roaming and service advertising capabilities. 
 
Extensive research in agent systems has been conducted in Europe, as evidenced by the reach of the 
AgentLink membership [21]. Data mining agents present human researchers with a set of potential 
hypotheses deduced from the data sources. Thus, with the information explosion caused by genomics and 
proteomics research, there is a great need for automated information-gathering agents in order to assist 
human researchers conducting automated or semi-automated testing of data. Nevertheless, scant multi-
disciplinary research has been channelled to the bioinformatics domain, where numerous databases and 
analysis tools are independently administered in geographically distinct localities, lending themselves almost 
ideally to the adoption of a multi-agent approach. 
 
Initiatives such as the “Modelling Adult Stem Cells as Multi-agent Systems” [8] in the UK, the ones 
emanated from the Cesena group in Italy [4], BioAgents [14], and InterLab [18] present some innovative 
approaches to agent systems in the biological sciences in Europe. Furthermore, GeneWeaver [11], DECAF 
[5], and MIAKT [15] introduce the use of agents and web services to genome analysis and decision support. 
In particular, MIAKT, provides support for Multi-Disciplinary Meetings (MDMs) between medical 
practitioners with different expertise, helping them to perform a collaborative diagnosis and plan of action 
for symptomatic, focal breast diseases. 
  
 
Fig. 1: Mean short echo spectra of representative pathologies in a validated-DB from the INTERPRET project [9]. 
These were obtained by averaging spectra normalized to the Euclidian norm. The vertical axis is displayed in the 
same arbitrary units (a.u.) scale for all types. The horizontal axis labels ppm values. Number of cases of each type in 
parentheses. The most relevant metabolites are: lipids, 0.9 and 1.29 ppm; N-acetyl-containing compounds, 2.03 
ppm; acetate, 1.9 ppm; macromolecules and glutamate/glutamine containing compounds, 2-2.5 ppm; creatine, 3.03 
ppm; choline-containing compounds, 3.21 ppm; myo-inositol and glycine, 3.55 ppm; glutamate/glutamine-
containing compounds and alanine, 3.77 ppm. (Adapted from Figure 4 of [19]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)          (b) 
Fig 2: (a) Molecular image of Cho (choline) concentration distribution from CSI spectra of a patient with a 
Glioblastoma (red indicates highest Cho levels in the tumour) including the deconvoluted spectrum. (b) CSI spectra 
from the rear cavity with a demyelisation lesion. The nine spectra shown, from the selected green square, present the 
most abnormal region bottom right (Images generated using SIView 2.0 [12]) 3 ARCHITECTURAL SPECIFICATION 
By focusing on brain tumour diagnosis and prognosis, 
the project is to apply agent technology to communicate user 
sites with a central database. It will employ agent 
negotiation and argumentation mechanisms developed for 
distributed resource allocations problems.  
 
Moreover, HealthAgents intends to build a completely 
distributed repository with local databases. Grid 
technologies such as multi-site data partition and distributed 
data sharing will permit the seamless access to different 
databases across sites.  
 
                                                                 Fig 3: HealthAgents multi-layer framework. 
 
We argue that a d-DSS will furnish a completely new approach to the brain tumour diagnosis. Since 
inferences from local predictions may well conflict with one another, reasoned argument between intelligent 
agents, acting on behalf of scientists, in a multi-agent system, will foster consensus. 
 
The HealthAgents project intends to not only apply agent technology into the biomedical field in a 
multi-disciplinary fashion, but also develop the first distributed repository for brain tumour diagnosis, 
leading eventually to the formation of a special interest data grid. 
 
A centralised DSS is already available from the INTERPRET project [9,20] to facilitate the clinical 
use of MRS in brain tumour diagnosis which uses a classification based on histopathological diagnosis. A 
more elaborated DSS, combining MRS biochemical profiles from Single Voxel (SV) and metabolic spatial 
distribution by Chemical Shift Imaging (CSI) MRS in vivo data, is currently being developed and 
implemented in the eTUMOUR project [6]. The eTUMOUR DSS will eventually improve and facilitate the 
clinical application of MRS in adults and paediatric brain tumour diagnosis, prognosis and treatment 
selection using a classification based in the combination of histology results and high resolution metabolic 
profiles (HR-MAS) and transcritptomic (DNA micro-arrays) ex vivo data.  
 
The HealthAgents d-DSS will build upon these projects and include additional MRS data, such as 
childhood tumours and less common adult tumours, using new classifications based on genetics. The 
development of this new d-DWH (the “d-DSS”), incorporating concepts of networking, agent technology, 
and data mining, must increase the number of accessible cases, yielding to an improved classifier, that in turn 
will achieve the goals described in this proposal. 
 
HealthAgents proposes a multi-layer system architecture as depicted in Fig. 3. The database-mapping 
layer is used to map a relational database schema to the HealthAgents ontological schema. The programming 
API layer abstracts the underlying database interaction from the agent architecture. The business methods 
layer contributes to the main control flow of an agent such as the new case classification, new classifiers 
reception, and data retrieval.  
 
The security and trust layer is a crucial system component due to the sensitivity of the data.  Its 
functionalities are access control, data marshalling, track out of on-going data, and the evaluation of 
reputation and trust of agents. The agent layer is in charge of all the communications and allows their 
abstraction from the rest of the system to allow flexibility in the underlying framework. The semantic 
description layer will contain the description of what the agent holds and what is able to do. 4 CONCLUSIONS 
In vivo MRS combined with in vitro MAS and gene expression promises to improve the classification 
of brain tumours and yield novel biomarkers for prognosis. Considerable amounts of highly complex data are 
required to build reliable specific tumour classifiers and it is a challenge to collect and manage this data. 
HealthAgents will address this problem by building a distributed system of databases centred on the users 
and managed by agents. As a result, HealthAgents proposes a unique blend of state-of-the-art technologies to 
develop novel clinical tools for the diagnosis, management and understanding of brain tumours. 
 
We have introduced the HealthAgents project, its objectives, and scope. Although tangible results are 
to be produced soon, we strongly believe that the conditions are given to produce an innovative software 
system to help in the fight against one of the most pernicious diseases of our time: cancer.  
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